linjc16/ctgov huggingface dataset:
Chronic Obstructive Pulmonary Disease and Pulmonary Hypertension: Prevalence and Quality of Life

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the prevalence of pulmonary hypertension (PH) among patients suffering from Chronic Obstructive Pulmonary Disease (COPD) and to assess the quality of life in those patients with concomitant PH compared to COPD patients without PH and those only suffering from pulmonary arterial hypertension (PAH) respectively.

Official Title
-----------------
Chronisch Obstruktive Lungenerkrankung Und Pulmonale Hypertonie: Prävalenz Und Lebensqualität

Conditions
-----------------
Hypertension, Pulmonary, Pulmonary Disease, Chronic Obstructive

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years Known or newly diagnosed COPD or PAH Written informed consent Present long-term oxygen treatment is no exclusion criterion Exclusion Criteria: Age < 18 years Right-heart catheterization not reasonable Pregnancy, Lactation Life expectancy <12 months due to any diseases aside from COPD Any medical, psychological or other condition, which limits the patient's ability to provide informed consent No written informed consent provided Current participation in another clinical trial

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| COPD with PH<br>COPD patients with confirmed diagnosis of PH. | |
| COPD without PH<br>COPD patients without confirmed diagnosis of PH | |
| PAH without COPD<br>PAH patients who do not suffer from COPD | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of PH | Prevalence of PH as defined by ESC/ERS guidelines (mean pulmonary arterial pressure ≥25 mmHg, assessed by right-heart catheterization) among the subgroup of COPD GOLD III and IV patients. | At baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life | Explorative data analysis to assess correlation between quality of life and PH, by comparison of COPD patients with and without PH and a reference group of patients with only PAH. | One year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pulmonary Hypertension, Chronic obstructive pulmonary disease, Prevalence, Quality of life
The Evaluation of Thiol Redox Status in Conjunctiva of Dry Eye Patients

Study Overview
=================
Brief Summary
-----------------
Dry eye disease is related with oxidative stress at the ocular surface. GSH is one of the key factor of protect from oxidative stress. To evaluate thiol status of ocular surface cells by monitoring GSH concentration, we can evaluate the severity of dry eye.

Detailed Description
-----------------
The conjunctival cells are collected by impression cytology. Those cells are stained with 100 mM of monochlorobimane (MCB, M-1381, Molecular Probes, Eugene, OR) and propidium iodide (PI). Fluorescent intensity, reflecting the amount of icGSH, was inspected under a confocal laser scan microscope. To detect the GSH levels we used a fluorescent MCB probe with excitation and emission wavelengths of 405 nm and 410-480 nm, respectively. The cell-permeating MCB probe is non-fluorescent but forms a fluorescent adduct with GSH in a reaction catalyzed by glutathione-S-transferase.

Official Title
-----------------
The Evaluation of Thiol Redox Status in Conjunctiva of Dry Eye Patients

Conditions
-----------------
Dry Eye Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: dry eye patients control volunteers Exclusion Criteria: Young (less than 20) patients The patients who rejected this study

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Sjogren<br>Sjogren syndrome with dry eye | |
| non-Sjogren<br>dry eye without Sjogren syndrome | |
| Short-BUT<br>Dry eye by shortened tear break up time | |
| control<br>normal patients | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tear amount, tear break up time, and so on are measured clinically. The thiol redox status is measured by staining the membrane. |  | Once a month (totally 2-4 times) at the clinic | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dry eye, Thiol redox, Oxidative stress
An Open-Label Study Investigating the Effects of Early Skin Barrier Protection on the Development of Atopic Dermatitis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether early use of a bland emollient in newborns, prior to the clinical signs of skin disease, will delay the onset or prevent the development of atopic dermatitis.

Detailed Description
-----------------
All neonates will be treated with Cetaphil cream starting within 1 week of birth. All neonates enrolled will have an increased risk of developing atopic dermatitis because they have a family history of either asthma, hay fever, or atopic dermatitis. These neonates will then be followed for 2 years for the signs and symptoms of atopic dermatitis.

Official Title
-----------------
An Open-Label Study Investigating the Effects of Early Skin Barrier Protection on the Development of Atopic Dermatitis

Conditions
-----------------
Atopic Dermatitis

Intervention / Treatment
-----------------
* Drug: emollient (Cetaphil cream)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: at least one parent diagnosed with Atopic Dermatitis one parent or sibling with hayfever or asthma Exclusion Criteria: newborns with dermatitis at birth newborns born greater than four weeks prematurely newborns with medical problems necessitating prolonged hospitalization newborns diagnosed with any immune deficiency syndrome

Ages Eligible for Study
-----------------
Maximum Age: 1 Month

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Emollient<br>Skin barrier protection from birth | Drug: emollient (Cetaphil cream)<br>* Cetaphil cream applied daily from birth<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of Skin Irritation |  | 1 and 2 year time points | 
| Incidence of Skin Infection |  | 1 and 2 year timepoints | 
| Compliance With Protocol |  | over two years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Development of Eczema |  | 1 and 2 year time points | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prevention, Atopic Dermatitis, Skin Barrier
CPAP/PSV Preoxygenation in Obese Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether continuouse positive airway pressure (CPAP), during induction of anaesthesia in morbidly obese patients, result in higher levels of oxygen in the blood.

Official Title
-----------------
Continuous Positive Airway Pressure/Pressure Support Preoxygenation of Morbidly Obese Patients

Conditions
-----------------
Obesity, Anaesthesia

Intervention / Treatment
-----------------
* Procedure: CPAP 5 cm H2O + PSV 5 cm H2O


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: body mass index (BMI) > 35 kg/m2 scheduled to undergo elective gastric bypass surgery age ≥ 18 years ASA Physical Status Classification II-III Exclusion Criteria: significant cardiopulmonary disease previous abdominal or thoracic surgery inability to comprehend the protocol.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control group<br>Neutral pressure breathing after 2 min preoxygenation | |
| Active Comparator: Active group<br>CPAP 5cm H2O + PSV 5cm H2O breathing after 2 min preoxygenation | Procedure: CPAP 5 cm H2O + PSV 5 cm H2O<br>* Patients in the intervention group received Continuous Positive Airway Pressure (5 cm H2O) and Pressure Supported Ventilation (5 cm H2O)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Post intubation PaO2levels | PaO2 levels is measured within 5 minutes after the completion of intubation. | 5 minutes after intubation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Obesity, general anaesthesia, preoxygenation, atelectasis
Reliability of Different FOT Devices to Measure the Human Respiratory Impedance

Study Overview
=================
Brief Summary
-----------------
The objective of the study is to evaluate the reliability of the impedance data in adult subjects measured with five different FOT devices.

Detailed Description
-----------------
The purpose of the study is to evaluate the reliability of the respiratory impedance measured with different FOT (=Forced Oscillation Technique) devices. To this end, the respiratory impedance of fifty adult subjects will be measured in random order with five different forced oscillation devices. As there is no gold standard FOT-device, each setup will be compared to all other setups. Secondary study questions are: 1) is there a specific comfort (or discomfort) associated with the different measuring devices 2) Guidelines state that full chin and cheek support should be applied when measuring the human respiratory impedance. What is the influence of a partial cheek support?

Official Title
-----------------
Comparison of the Reliability of Different Devices to Measure Lung Function With the Forced Oscillation Technique

Conditions
-----------------
Pulmonary Disease, Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy adult subjects Adult patients with obstructive lung disease Exclusion Criteria: Inability to perform lung function tests Patients with respiratory failure Patients on BIPAP-therapy Patients on supplemental oxygen.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Adult lung function<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of the respiratory impedance measured with two different FOT devices | Bland-Altman plot of Zrs measured with two devices | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Subjective evaluation of the Zrs-measurement with a specific FOT device by the investigated subject. | Rating of the subjective experience of the Zrs-measurement with a specific FOT device | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Respiratory resistance, Respiratory reactance, Adult lung function, Forced oscillation technique, subjects
High-flow Nasal Cannula Nebulization of Beta 2 Adrenergic Agonist During Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Study Overview
=================
Brief Summary
-----------------
High-flow nasal cannula is an oxygenation technique increasingly used for patients admitted for acute respiratory failure. Literature essentially concerns de novo acute hypoxemic failure and the interest of high-flow during take care of chronic obstructive pulmonary disease patients is few studied. Physiological studies reported potential benefits of high-flow nasal cannula oxygenation in chronic obstructive pulmonary disease patients including dead space clearance and decrease of respiratory, which lead to decrease work of breathing. As inhaled bronchodilators are part of treatment of chronic obstructive pulmonary disease exacerbation, nebulization could be also provided through high-flow nasal cannula oxygen therapy. The aim of our study is to determine whether a beta-2 agonist nebulization administered through High-flow nasal cannula is efficient to improve spirometry of patients for admitted hronic obstructive pulmonary disease exacerbation.

Official Title
-----------------
High-flow Nasal Cannula Nebulization of Beta 2 Adrenergic Agonist During Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Conditions
-----------------
Chronic Obstructive Pulmonary Disease, High-flow Nasal Cannula

Intervention / Treatment
-----------------
* Drug: salbutamol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Arterial pH over 7.25, Respiratory rate under 35 breaths/mn Glasgow Coma Scale equal to 15, indication of beta-2 agonist nebulization less than 8 per day (time between two nebulization more than 3 hours), NIV sessions spaced more than 6 hours. Exclusion Criteria: Urgent endotracheal intubation; Contraindication to beta 2 adrenergic agonist; Another organ failure (hemodynamic and neurological instability); Cardioselective beta-blocker during treatment of copd exacerbation;

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: TREATMENT<br>salbutamol nebulization | Drug: salbutamol<br>* T2 - T1+1h30: High-nasal flow and salbutamol nebulization<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| compare lung functions | Evolution of Forced Expiratory Volume 1s | baseline-1h30 |
Implementation of a GDT Algorithm for Major Surgery Patients

Study Overview
=================
Brief Summary
-----------------
This study examines the effect of an algorithm for GDT for patients undergoing major surgery under routine conditions.

Detailed Description
-----------------
Goal directed fluid management in major abdominal surgery has been shown to reduce perioperative complications. The approach aims to optimize the intravascular fluid volume by use of minimally invasive devices which calculate flow-directed variables such as stroke volume (SV) and stroke volume variation (SVV). The investigators aim to show the feasibility of routinely implementing such hemodynamic monitoring during major abdominal surgery, and to evaluate its effects in terms of perioperative fluid management and postoperative outcomes.

Official Title
-----------------
Implementation and Effects of Pulse-contour-automated SVV/CI Guided Goal Directed Fluid Therapy Algorithm for the Routine Management of Major Abdominal Surgery Patients

Conditions
-----------------
Colectomy, Pancreatectomy, Fluid Therapy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pancreatic surgery colorectal surgery Exclusion Criteria: admission for revisional surgery
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Standard therapy<br>intraoperative standard fluid therapy for major abdominal surgery | |
| Goal directed therapy<br>intraoperative goal directed fluid therapy based on an angorithm lead by SVV/CI for major abdominal surgery patients | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Length of stay in hospital |  | 90 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| intraoperative crystalloid volume |  | 1 day | 
| intraoperative colloid volume |  | 1 day | 
| Length of stay at ICU |  | 90 days | 
| Total amount of complications per patient |  | 90 days | 
| Insufficiance of bowel anastomosis |  | 90 days | 
| Pneumonia |  | 90 days | 
| ACS |  | 90 days | 
| acute renal failure |  | 90 days | 
| Sepsis |  | 90 days | 
| Intraabd. Infection |  | 90 days | 
| wound infection |  | 90 days | 
| UTI |  | 90 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Major abdominal surgery, Goal directed therapy
Bipolar Surgical Release in Congenital Muscular Torticollis

Study Overview
=================
Brief Summary
-----------------
The congenital muscular torticollis is common disease in children.The indication for surgery is the children have persist deformity after 1 year old.Many surgical treatment had proposed such as unipolar release and bipolar release.By author experience the bipolar release had better results from complete cut the muscle both origin and insertion.This study wants to study the results of treatment in term of recurrence of the deformity.

Detailed Description
-----------------
the study perform in children with congenital muscular torticollis

Official Title
-----------------
Result of Bipolar Surgical Release in Congenital Muscular Torticollis

Conditions
-----------------
Congenital Muscular Torticollis

Intervention / Treatment
-----------------
* Procedure: bipolar release


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. all children age ranged from 5-15 years old who received the surgical treatment by bipolar release in the hospital. Exclusion Criteria: 1. no history of surgery at the neck 2. no history of congenital anomalies and syndrome that effect the neck

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: only 1 group in children who received the bipolar release
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: children who had bipolar release<br>children who had bipolar release are included | Procedure: bipolar release<br>* the bipolar release is the surgery that cut the origin and insertion of the sternocleidomastoid muscle that cause the torticollis from its contracture<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ImageJ scoring system | measurement from pictures of head and face compared to normal children score 1-3 in 5 measurement in total score of 15 as interval scale score has 4 grade 13-15 is excellent results score 10-12 good result 7-9 fair less than 6 score is poor result after surgery | no torticollis after 1 year of surgery |
Changes in Metabolic Status in Patients With Total Thyroidectomy

Study Overview
=================
Brief Summary
-----------------
This study objective is to evaluate the change in mitochondrial uncoupling protein 2 (UCP2) mRNA expression as function of thyroid activity (TSH, T3 and Free T4).

Detailed Description
-----------------
Blood will be drown before thyroidectomy, 2 weeks after the operation and 3-4 month after the operation.

Conditions
-----------------
Thyroid Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who were diagnosed with thyroid carcinoma and are going to have total thyroidectomy. Patients with unbalanced thyroid hormones. Aged 18-65 years at the time of screening. Provision of written informed consent. Exclusion Criteria: Patients with Diabetes. Patients with any other chronic inflammatory diseases. Steroid treatment.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in UCP2 mRNA concentrations. | The difference between the result at two weeks and four months compare to base line. | Base line (before opporation), 2 weeks after opporation and for after opporation. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Weight |  | Approximately 4 months | 
| Resting energy expenditure |  | Approximatly 4 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
UCP2, Thyroid function, Thyroid carcinoma